CDX2 and gastric cancer: Based on the RNA‐sequencing data of patients with stage II/III gastric cancer from the public ACRG cohort, there were 39 genes upregulated and 194 genes downregulated in the CDX2‐negative subgroup when compared with the CDX2‐positive subgroup (p < 0.05, false discovery rate <0.25) (Figure 6A).